ABBOTT LABORATORIES
Ownership & governance
Executives 5Directors 10Avg age 60Avg tenure 7.5y
RF
Robert Ford
Chief Executive Officer
Age 52Since 2020-03-30Profile →
+14
Executives5
Board of directors10
SB
Sally Blount→
Director/Board Member
Age 64Since 2011-12-08
NM
Nancy McKinstry→
Director/Board Member
Age 67Since 2011-12-08
DS
Daniel Starks→
Director/Board Member
Age 71Since 2017-02-15
JS
John Stratton→
Director/Board Member
Age 65Since 2017-06-28
RF
Robert Ford→
Chairman
Age 52Since 2021-12-09
MK
Michelle Kumbier→
Director/Board Member
Age 58Since 2018-06-07
DM
Darren McDew→
Director/Board Member
Age 65Since 2019-09-08
MR
Michael Roman→
Director/Board Member
Age 66Since 2021-04-22
Shareholders4
| Name | Stake | Shares |
|---|---|---|
| Vanguard Capital Management LLC | 6.485 % | 112,949,933 |
| BlackRock Advisors LLC | 6.339 % | 110,412,900 |
| STATE STREET CORPORATION | 4.569 % | 79,575,468 |
| Capital Research & Management Co. (Global Investors) | 2.858 % | 49,775,362 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Lisa Earnhardt | Chief Tech/Sci/R&D Officer | 2019-05-31 | - |
| Philip Boudreau | Director of Finance/CFO | 2023-08-31 | - |
| Robert Ford | Chief Executive Officer | 2020-03-30 | - |
| Robert Ford | Chairman | 2021-12-09 | - |
| Sabina Ewing | Chief Investment Officer | — | - |
| Scott House | Chief Tech/Sci/R&D Officer | 2019-10-31 | - |
| Claire Babineaux-Fontenot | Director/Board Member | 2022-09-14 | - |
| Daniel Starks | Director/Board Member | 2017-02-15 | - |
Registry · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| TwistDx Ltd. | Biotechnology |
| St. Jude Medical International Holding SARL | Medical Distributors |
| St. Jude Medical Luxembourg SRL | Financial Conglomerates |
| St. Jude Medical Luxembourg SRL | Financial Conglomerates |
| Abbott Laboratories GmbH | Pharmaceuticals: Major |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 120.72Range 103–135Analysts 26
103Mean 120.72135
- Strong buy 5
- Buy 19
- Hold 4
Broker actions40 of 430
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Barclays | Initiated | Overweight | 120 | 2026-10-07 |
| Rothschild & Co | Upgrade | Buy | 127 | 2026-10-02 |
| TD Cowen | Reiterated | Buy | 135 | 2026-09-08 |
| TD Cowen | Maintained | Buy | 135 | 2026-08-25 |
| TD Cowen | Maintained | Buy | 135 | 2026-08-21 |
| Citigroup | Maintained | Buy | 125 | 2026-08-14 |
| Wolfe Research | Upgrade | Outperform | 130 | 2026-08-13 |
| UBS | Maintained | Buy | 125 | 2026-07-28 |
| Citigroup | Maintained | Buy | 112 | 2026-07-17 |
| Piper Sandler | Reiterated | Overweight | 118 | 2026-07-17 |
| JP Morgan | Maintained | Overweight | 120 | 2026-07-17 |
| Wells Fargo | Maintained | Overweight | 112 | 2026-07-17 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.